S&P 5007,691▲ 0.41%Nasdaq26,431▲ 1.11%Dow Jones51,966▼ 0.07%Nasdaq 10029,529▲ 1.17%VIX18.44▼ 7.75%US Dollar101.97▲ 0.13%Gold spot4,165▲ 0.21%WTI spot101.91▲ 1.04%
Home › BRN › Research report
← BRN page
XStocksXray
Market X-Ray report · 19 October 2026

Brainchip Holdings Ltd (BRN)

Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026

Key indicators

Last closeAUD 0.120
52-week range0.113 – 0.215
Return, 1 month / 3 months−11.1% / −7.7%
Return, 1 year / 3 years−40.0% / −33.3%
TrendBelow its 200-day average
RSI (14)38
Volatility (1 year)58.2%
Worst drawdown (1 year)-42.5%
Average daily value traded0.38M AUD
Dividend yield–

Market X-Ray price-based

55/ 100 · High confidence · ahead of 56% of stocks on this exchange
Trend46
Momentum41
Stability (higher is calmer)67
Liquidity73
Income–

Five-year price chart navy: price · brown: 200-day average

-0.010.561.121.692.252021-102023-012024-042025-072026-10

About the company

BrainChip Holdings develops neuromorphic computing technology designed to mimic aspects of how the brain processes information. Its main offering is the Akida family of event-based neural processing devices, which are built for artificial intelligence tasks at the edge of networks, such as sensing and pattern recognition in connected devices. The company works with partners and customers in electronics and semiconductor markets, and it is based in Australia.

The shares are listed on the Australian Securities Exchange in Australia under the code BRN, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Brainchip Holdings Ltd (BRN) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.120 on 19 October 2026.

Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 800 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 40.0% and over the last three months it fell 7.7%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Brainchip Holdings Ltd (BRN)

The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange

Lens and metricValueScoreReading
Trend46 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-17.9%
From 52-week high-40.0%
Momentum41 · WeakLagging most stocks on this exchange.
3-month return-7.7%
6-month return-22.6%
12-month return, skipping the last month-32.5%
Stability (higher is calmer)67 · FairTypical risk for this exchange.
Volatility, 1 year (lower is calmer)58.2%
Worst drawdown, 1 year (smaller is calmer)-42.5%
Liquidity73 · StrongTrades actively.
Average daily value traded0.38M AUD
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Liquidity: Trades actively.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Momentum: Lagging most stocks on this exchange.

Returns

1 week−4.0%
1 month−11.1%
3 months−7.7%
6 months−22.6%
1 year−40.0%
3 years−33.3%
5 years−75.8%

Signals

50-day / 200-day average0.131 / 0.146
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.007

Technical summary

DailyStrongly bearish1 bullish · 3 neutral · 12 bearish
WeeklyStrongly bearish0 bullish · 1 neutral · 11 bearish
MonthlyStrongly bearish0 bullish · 1 neutral · 7 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 20 Oct 2026